Cargando…
Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study
SIMPLE SUMMARY: In nuclear medicine, therapeutic methods are used increasingly, in which tumors are destroyed by ionizing radiation that cannot or can only be treated insufficiently by other methods like surgery or chemotherapy. Targeted alpha therapy (TAT) is a promising method with increasing impo...
Autores principales: | Reissig, Falco, Bauer, David, Zarschler, Kristof, Novy, Zbynek, Bendova, Katerina, Ludik, Marie-Charlotte, Kopka, Klaus, Pietzsch, Hans-Jürgen, Petrik, Milos, Mamat, Constantin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073976/ https://www.ncbi.nlm.nih.gov/pubmed/33923965 http://dx.doi.org/10.3390/cancers13081974 |
Ejemplares similares
-
Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin
por: Reissig, Falco, et al.
Publicado: (2022) -
Sub‐10 nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy
por: Reissig, Falco, et al.
Publicado: (2020) -
A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225
por: Salvanou, Evangelia-Alexandra, et al.
Publicado: (2020) -
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022) -
A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)